Revive Therapeutics Ltd (RVVTF)

[Natural Trader]

The FDA recommended that the Company proceed directly into a Phase 3 confirmatory clinical trial (“Phase 3 study”) to evaluate Bucillamine for the treatment of patients with mild-moderate COVID-19 due to the SARS-CoV-2 infection in order to ensure expeditious evaluation of the safety and efficacy of Bucillamine.
https://www.globenewswire.com/news-release/2020/04/23/2020948/0/en/Revive-Therapeutics-Announces-U-S-FDA-Recommendation-to-Proceed-Directly-Into-A-Phase-3-Confirmatory-Clinical-Trial.html